AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...
Zacks Investment Research on MSN1d
Analysts Estimate FactSet Research (FDS) to Report a Decline in Earnings: What to Look Out forWall Street expects a year-over-year decline in earnings on higher revenues when FactSet Research (FDS) reports results for the quarter ended February 2025. While this widely-known consensus outlook ...
“I want to thank Yet for his outstanding leadership and contributions to maintaining strong investor engagement during his time in the investor relations role,” said Helen Shan, Chief Financial ...
FactSet (FDS) has appointed Kevin Toomey as Head of Investor Relations, effective immediately. He will replace Yet He, who served as Interim ...
Buffett is a long-term value investor who often holds stocks for decades, so you won't find him chasing the latest market ...
Analysts have set 12-month price targets for FactSet Research Systems, revealing an average target of $482.29, a high estimate of $518.00, and a low estimate of $409.00. This current average has ...
President Donald Trump's penchant for tariffs has raised recession fears in the stock market, yet companies aren't talking much about that growing worry.
Mutual of America Capital Management LLC decreased its position in FactSet Research Systems Inc. (NYSE:FDS – Free Report) by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback